Science News
from research organizations

Cannabinoid shown effective as adjuvant analgesic for cancer pain

Date:
June 4, 2012
Source:
American Pain Society
Summary:
An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial.
Share:
         
Total shares:  
FULL STORY

An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.

While opioid therapy is the mainstay treatment for cancer pain in patients with advanced disease, a substantial minority experience pain that cannot be adequately controlled at safe and tolerable doses. The most common treatment approach is co-administration of another analgesic. Cannabinoids are being analyzed as potential adjuvant analgesics. In this randomized multicenter study, nabiximols, a cannabinoid delivered as an oral mucosal spray, was studied to obtain information about the dose response for analgesia and safety in a population with pain not adequately controlled with an opioid.

Patients were eligible to participate in the study if they had active cancer and chronic pain that was moderate to severe despite taking opioids. The study timeline was a five to 14 day baseline period, five weeks titration and treatment, and a post-study visit after two weeks. Every day, patients responded to questions to rate their pain, gauge their sleep quality, and determine how many sprays of the nabiximols they were taking.

Results of the study showed that nabiximols has analgesic efficacy when used as an add-on therapy for cancer patients with pain not controlled by an opioid alone. In the low-dose nabiximols group, there was a 25 percent improvement in pain compared with baseline. However, there was no analgesic effect in the high-dose group and the high dose was not well tolerated. Just 66 percent of subjects in that group finished the study. The authors concluded that nabiximols in a tolerable dose range may offer analgesic benefits to very ill cancer patients with refractory pain.


Story Source:

The above story is based on materials provided by American Pain Society. Note: Materials may be edited for content and length.


Cite This Page:

American Pain Society. "Cannabinoid shown effective as adjuvant analgesic for cancer pain." ScienceDaily. ScienceDaily, 4 June 2012. <www.sciencedaily.com/releases/2012/06/120604142426.htm>.
American Pain Society. (2012, June 4). Cannabinoid shown effective as adjuvant analgesic for cancer pain. ScienceDaily. Retrieved April 27, 2015 from www.sciencedaily.com/releases/2012/06/120604142426.htm
American Pain Society. "Cannabinoid shown effective as adjuvant analgesic for cancer pain." ScienceDaily. www.sciencedaily.com/releases/2012/06/120604142426.htm (accessed April 27, 2015).

Share This Page:


Health & Medicine News
April 27, 2015

Latest Headlines
updated 12:56 pm ET